Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

2020 TTF RARE Mutations - Sands - Casting a Wide Net: The Need for Broad Molecular Testing
2020 Targeted Therapies Patient Forum - RARE Mutations Dr. Jacob Sands - Casting a Wide Net: The Need for Broad Molecular Testing
Author
Denise Brock
Image
We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum.

This event's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.

This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer.

 

In this video from the Rare Mutations session from the event, Dr. Jacob Sands discusses the need for broad molecular testing.

 

We thank our sponsors for their support of this event! AstraZeneca, Lilly, Novartis, Takeda, Foundation Medicine, Boehringer Ingelheim, Blueprint Medicines and Genentech

Access to the full agenda can be found here: https://bit.ly/39131em

Full bios for attending faculty can be found here: https://bit.ly/2M0FVLH

To join the conversation, visit https://cancergrace.org/forum.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora